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Abstract
Background: Schistosomiasis is one of the major health problems in tropical and sub-tropical
countries, with school age children usually being the most affected group. In 1998 the Department
of Health of the province of KwaZulu-Natal established a pilot programme for helminth control
that aimed at regularly treating primary school children for schistosome and intestinal helminth
infections. This article describes the baseline situation and the impact of treatment on S.
haematobium infection in a cohort of schoolchildren attending grade 3 in a rural part of the
province.
Methods: Primary schoolchildren from Maputaland in northern KwaZulu-Natal were examined
for Schistosoma haematobium infection, treated with praziquantel and re-examined four times over
one year after treatment in order to assess the impact of treatment and patterns of infection and
re-infection.
Results: Praziquantel treatment was highly efficacious at three weeks after treatment when judged
by egg reduction rate (95.3%) and cure rate of heavy infections (94.1%). The apparent overall cure
rate three weeks after treatment (57.9%) was much lower but improved to 80.7% at 41 weeks after
treatment. Re-infection with S. haematobium was low and appeared to be limited to the hot and
rainy summer. Analysis of only one urine specimen per child considerably underestimated
prevalence when compared to the analysis of two specimens, but both approaches provided similar
estimates of the proportion of heavy infections and of average infection intensity in the population.
Conclusion: According to WHO guidelines the high prevalence and intensity of S. haematobium
infection necessitate regular treatment of schoolchildren in the area. The seasonal transmission
pattern together with the slow pace of re-infection suggest that one treatment per year, applied
after the end of summer, is sufficient to keep S. haematobium infection in the area at low levels.
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Background
Schistosomiasis is one of the major health problems in
tropical and sub-tropical countries [1]. The schistosomia-
sis endemic area in South Africa is situated in the north-
east and covers roughly one quarter of the country, with
Schistosoma haematobium being the most common species
[2]. In 1995 it was estimated that more than four million
South Africans were infected with schistosomes [3].
Possible consequences of S. haematobium infection
include haematuria, dysuria, nutritional deficiencies,
lesions of the bladder, kidney failure, an elevated risk of
bladder cancer and – in children – growth retardation.
Accordingly the estimates for morbidity and mortality in
affected populations are high [4-7]]. School age children
usually present with the highest prevalence and intensity
of S. haematobium infection [8]. However, negative health
consequences are not limited to this group since high
intensity infections can cause serious chronic disease long
after initial infection [9]. Some studies also suggest that
schistosomiasis may play a role as a risk factor for HIV
infection and that helminth infections in general nega-
tively affect the immune system of HIV infected persons
[10,11].
In 1998 the Department of Health of the province of Kwa-
Zulu-Natal (KZN) in co-operation with the Department of
Education established a pilot programme for helminth
control that aimed at regularly treating primary school
children for schistosome infections and intestinal
helminth infections [12]. All children in participating
schools were treated without prior screening of infection
status. The rationale behind this and similar programmes
in other countries is not to eliminate infection in a given
area, but to keep infection intensities low in this vulnera-
ble age group in order to prevent serious morbidity
[13,14].
Our objectives were to describe the pattern of schistosome
infection at baseline, to monitor the impact of treatment
in our study population and to assess re-infection after
treatment in order to develop recommendations for
future control activities.
Methods
Study area, population and treatment
The study was conducted in central Ingwavuma district in
northern KwaZulu-Natal (Figure 1). The study area covers
approximately 28 × 16 km on both sides of the perennial
Pongola River (Figure 2). Climate is tropical to subtropi-
cal (Figure 3) with a hot and wet summer (November –
February) and a cooler and dry winter (June – August).
The study population (Table 1) was recruited from all ten
primary schools in the area. It was limited to children who
attended grade 3 at the start of the study in order to keep
disturbances of the school routine to a minimum and
because this grade should represent the infection situation
in a primary school relatively well [15]. All grade 3 pupils
were eligible for participation with one exception: during
the baseline survey two out of five and one out of four
grade 3 classes in two large schools had to be excluded due
to logistic constraints. These classes, however, were
included during treatment and successive surveys.
All pupils who provided a urine specimen during the pre-
treatment survey were included in the analysis of infection
patterns at baseline but only children who had been
treated with praziquantel were included in the analysis of
the post-treatment surveys. Of these, another 4.6% who
reported having received additional treatment for schisto-
some infection while our study was ongoing were
excluded from analysis. Otherwise only children who
refused to participate or who were absent or unable to
produce a specimen during each of our repeated visits
Location of the study area in northern KwaZulu-Natal Figure 1
Location of the study area in northern KwaZulu-Natal.
Province of
KwaZulu-Natal
Swazi-
land
Mo-
zam-
bique
150
Kilometers
0
N
75
Lesotho
Durban
Study AreaBMC Infectious Diseases 2004, 4:40 http://www.biomedcentral.com/1471-2334/4/40
Page 3 of 10
(page number not for citation purposes)
Map of the study area Figure 2
Map of the study area.
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were not included in the analysis of the respective surveys.
They were included, however, for those surveys where
they participated in order not to increase bias due to the
likely difference in disease status between absentees and
pupils who attended school [16].
Treatment in all primary schools in the entire district was
carried out in April and May 1998 by school nursing
teams from the two local hospitals as part of the first treat-
ment campaign of a provincial helminth control pro-
gramme. The study team assisted the nurses with
treatment and also recorded those of the study population
who were treated and those who were not. All consenting
children from all grades were treated for schistosome
infection with a single dose of 40 mg/kg praziquantel (Bil-
tricide®, Bayer) without regard to infection status. In order
to facilitate administration of the drug, the nurses had
been provided with a dosing sheet that showed the correct
dosage for different bodyweights. The weight of the chil-
dren was determined using an ordinary bathroom scale.
Because one Biltricide® tablet containing 600 mg of prazi-
quantel can be subdivided into four segments of 150 mg
the required dose can be administered relatively accu-
rately. The drug was administered with a glass of water
after the children had eaten a peanut butter sandwich
which was provided by the treatment team. Children were
asked to swallow the tablets with some water in front of
one of the team in order to monitor adherence. Because
praziquantel is considered a safe drug and has been used
extensively since its introduction in the early 80ies possi-
ble side effects of treatment were not monitored systemat-
ically [17].
Children were also treated for intestinal helminth infec-
tion with 400 mg albendazole (Zentel®, SmithKline Bee-
cham) and albendazole treatment was repeated in
October 1998 [18]. After the end of the study the partici-
pants were included in the normal treatment routine of
the control programme.
Ethical considerations
Ethical clearance was obtained from the Ethics Committee
of the Faculty of Medicine of the University of Natal/Dur-
ban and the study was also approved by the Central Med-
ical Ethics Committee in Denmark. Before the onset of the
study, information meetings were held with the staff and
parents of the schools in the study. At these meetings
informed consent was obtained from the parents.
Informed consent from the children was obtained directly
before the first specimen collection.
Specimen collection and processing
An initial survey in March 1998 to assess S. haematobium
infection in the study population was followed by treat-
ment for schistosome and intestinal helminth infections.
Follow-up surveys to monitor loss of infection and re-
infection were conducted at 3, 16, 41 and 53 weeks after
treatment (Table 2).
Urine specimens were collected between 10:00 and 13:00
hours [13]. On our visits to the schools, pupils were pro-
vided with labelled 500 ml specimen containers and
asked to provide a urine specimen. Each school was vis-
ited at least three times during each survey in order to
include children who were absent or unable to deliver a
specimen on the first occasion. Apart from the pre-treat-
ment survey, where only one specimen was collected, an
effort was made to obtain two urine specimens from each
pupil. However, the results reported in this article are cal-
culated using only the first specimen obtained. Otherwise
the lower sensitivity of the pre-treatment survey would
have invalidated comparisons with the follow-up surveys.
The results of both obtained specimens are used only in
Table 2 where we directly compare them to those of only
one specimen.
Filled specimen containers were brought to the laboratory
where filtration of a sub-sample of 10 ml was carried out
Long-term monthly averages of rainfall and temperature in  the area Figure 3
Long-term monthly averages of rainfall and tempera-
ture in the area. Data from 1966 to 1990 for Makatini 
research station, about 30 km south of the study area [36].
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on the same day [19]. Specimens of less than 10 ml were
measured before filtration and the number of eggs per 10
ml calculated. Before microscopy, eggs were stained using
50% Lugol's iodine saline solution [20] and then counted
by 3 microscopists in order to obtain an indirect measure-
ment of infection intensity. These counts did not differen-
tiate between viable and non-viable eggs. Repeat counts
by different microscopists were done on a sub sample of
about 5% of the slides for quality control purposes. These
counts revealed no bigger discrepancies. Infection
intensities are expressed as eggs per centilitre (EPC, 1 cen-
tilitre = 10 ml).
Statistics
Data were double entered, the duplicates compared and
corrected for data entry errors. Statistical analysis was car-
ried out in Stata 7 for Windows [21].
In order to reduce the influence of extreme outliers, geo-
metric means were preferred to arithmetic means to sum-
marise population infection intensity (Table 1 and Table
2). Uninfected children were included by adding 1 to all
egg counts before log transformation and subtracting it
again after re-transformation. However, when comparing
intensity, non-parametric statistics were used because
even the log transformed egg counts were still far from
being normally distributed. Cure rates (CR) and egg
reduction rates (ERR) were calculated using the formulae
below [15]:
Results
Infection patterns at baseline
In the pre-treatment survey 68% of the study population
were found infected with S. haematobium and 38% (= 56%
of the infected children) had egg counts of 50 or more
Table 1: Age and sex of the study population and prevalence and intensity of Schistosoma haematobium infection at baseline
n = Males 510 Females 599 Male/Female Ratio 95%CI or P-value
Median age (inter-quartile range) 11.3 (9.8–12.2) 10.7 (9.7–11.5) - -
Prevalence (%) 65.9 70.3 0.937 0.864–1.017
Age adjusted prevalence ratio* - - 0.896 0.828–0.969
Prevalence of infections >= 50EPC in % 36.7 39.6 0.927 0.797–1.078
Geometric mean EPC incl. uninfected 14.3 17.8 0.805 p = 0.151†
*Mantel-Haenszel age adjusted male/female prevalence ratio
†Two-sided P-value of two samples Wilcoxon ranksum test with ties
Table 2: Schistosoma haematobium prevalence and infection intensity, cure rates and egg reduction rates at various periods after 
treatment with 40 mg/kg praziquantel
Weeks since treatment Pre-treatment 3 16 41 53
Time of survey Mar '98 May/Jun Aug Feb '99 Apr/May
n = 1109 977 922 848 825
First specimen only*
Prevalence (%) 68.3 28.8 18.7 13.2 20.1
Cure rate (%) - 57.9 72.7 80.7 70.5
Prevalence of infections >= 50 EPC (%) 38.2 2.3 2.1 1.9 4.1
Cure rate of infections >= 50 EPC (%) - 94.1 94.6 95.1 89.2
Geometric mean EPC incl. uninfected 16.1 0.8 0.4 0.3 0.6
Egg reduction rate (%) - 95.3 97.5 97.9 96.0
Both specimens†
Prevalence (%) - 39.9 29.3 17.6 28.7
Prevalence of infections >= 50 EPC (%) - 2.5 2.1 1.9 5.0
Geometric mean EPC incl. uninfected - 0.9 0.5 0.3 0.6
*Results obtained when utilising only the first of two specimens that were collected
†Results obtained when utilising both specimens that were collected
CR
% prevalence before treatment   % prevalence after trea
=
− t tment
% prevalence before treatment
100% ×
ERR
mean EPC before treatment   mean EPC after treatment
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−
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100% ×BMC Infectious Diseases 2004, 4:40 http://www.biomedcentral.com/1471-2334/4/40
Page 6 of 10
(page number not for citation purposes)
EPC, the WHO [4] threshold for heavy intensity infections
(Figure 4). As shown in Table 1, differences between sexes
regarding prevalence and intensity of S. haematobium
infection were moderate.
Figure 5 demonstrates that age patterns of infection at
baseline differed considerably between sexes. S. haemato-
bium prevalence of boys slowly increased from 60% in the
youngest to 79% in the oldest age group whereas the
youngest girls had a much lower prevalence (37%) but the
increase with age was steeper.
Treatment
Of the 1109 children who participated in the baseline sur-
vey only 852 (76.8%) were treated with praziquantel. 228
children (20.6%) did not receive treatment either because
they refused to be treated (7 children) or because they
were absent on treatment day (221) and for 29 children
(2.6%) it is unclear whether or not they were treated.
Differences between the treated and untreated groups
(excluding children of unclear treatment status) regarding
sex, age, infection status and infection intensity were
small and not statistically significant.
S. haematobium infection status, CR and ERR over 53
weeks after treatment are summarised in Table 2. Infec-
tion intensity measured as the geometric mean EPC had
decreased by more than 95% as soon as three weeks after
treatment and over the following months a further small
decrease is documented until 41 weeks after treatment.
The pattern for prevalence and CR of heavy intensity infec-
tions is very similar to this. Total prevalence shows the
same trend over time, but in contrast exhibits considera-
bly smaller decreases than the other two measures.
In Table 2 we also report the results that were obtained
when using both specimens that were collected in the
post-treatment surveys. When comparing the different
approaches it is obvious that – as expected – the use of
only one sample considerably underestimates the total
Schistosoma haematobium infection at baseline and at various periods after treatment Figure 4
Schistosoma haematobium infection at baseline and at various periods after treatment. Prevalence of infections >= 
any intensity threshold of interest can be read from the percentage scale. The intersection of each graph with the y-axis corre-
sponds to the total prevalence. For the number of participants in each survey see Table 2.
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prevalence in this population, but that estimates for prev-
alence of heavy infections and geometric mean intensity
are quite similar.
Re-infection
No discernible re-infection took place between 3 and 41
weeks after treatment (Table 2 and Figure 4) whereas the
increase between 41 and 53 weeks after treatment was
substantial (two-sided p < 0.001 for both prevalence and
intensity using the sign test for equality of paired observa-
tions [22]).
The group at risk of re-infection (Figure 5) was defined as
those children who were found uninfected in at least one
of the three surveys at 3, 16 or 41 weeks after treatment (n
= 796). Fifty-three weeks after treatment 16.8% of these
children were found to be re-infected with S. haemato-
bium. The geometric mean EPC including uninfected chil-
dren of 0.44 was still far below the corresponding figure
before treatment (16.08) and this was also true for the
geometric mean EPC when excluding uninfected children
(58.2 before treatment and 6.6 at 53 weeks after
treatment).
Figure 5 shows that the age pattern of re-infection in the
study population also differed between sexes: it continu-
ously decreased with age for boys but not for girls where
re-infection reached a peak in the group that had been 11
to 12 years old at the time of the baseline survey and that
was about 12 to 13 years old at the end of the study.
Prevalence of Schistosoma haematobium infection before treatment (baseline) and after 53 weeks of re-infection Figure 5
Prevalence of Schistosoma haematobium infection before treatment (baseline) and after 53 weeks of re-infec-
tion. Re-infection data only include children who were found egg-negative in at least one of the surveys at 3, 16 or 41 weeks 
after treatment. The table below the graph shows the number of participants in each age/sex stratum.
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Discussion
Infection patterns at baseline
The results of our baseline survey are in agreement with a
survey conducted in the area about 20 years earlier.
Schutte et al. [23] found prevalences of between 55% and
92% in the four surveyed schools that were situated in our
study area. The high total prevalence and the large propor-
tion of high intensity infections that we found indicate
that according to WHO criteria regular treatment of
schoolchildren in the area is indeed necessary [4]. The dif-
ferent age patterns for prevalence of S. haematobium infec-
tion in girls and boys might hint at different water contact
patterns.
Treatment
The proportion of children treated in our study can not be
regarded as representative for the control programme in
general, because study participants were more informed
about it than their schoolmates. However, the fact that
only about three quarters of the children were treated is
very disappointing. Although only 3 children did not con-
sent to participate in our study, and only 7 of those who
consented openly refused to be treated absenteeism was
unusually high during the first round of treatment. This
improved greatly in the second treatment half a year later,
when – according to the opinion of school staff – pupils
and their parents had realised that treatment was benefi-
cial and had only mild and transient side effects. Unfortu-
nately this second round of treatment did only include
albendazole but not praziquantel because the schedule of
the provincial treatment programme only provided one
treatment for schistosome infection per year.
Praziquantel treatment resulted in drastic reductions of
infection intensity and prevalence of heavy infections as
soon as three weeks after treatment, which is in accord-
ance with the literature [24]. The reduction in overall
prevalence of less than 60% at three weeks after treatment
is however unsatisfactory, even though it improved to
about 80% at 41 weeks after treatment. The explanations
that the treatment did not work or that its effect was
delayed can be excluded because of the high ERR. It seems
more likely that the relatively high post-treatment preva-
lences are not an indication of a high proportion of active
infections after treatment, but that they are caused by
"old" and mostly non-infective eggs, laid before treat-
ment, that were trapped somewhere in the tissue and are
slowly finding their way to the lumen of the bladder
[25,26]. Unfortunately our laboratory examination did
not differentiate between viable and non-viable eggs, but
the data presented in Figure 4 are consistent with the
above explanation because very little change is visible
between 3 and 41 weeks after treatment with regard to
infections of more than 50 EPC. During this period prev-
alence decreased almost exclusively in the low intensity
range. If many active infections (= egg laying schisto-
somes) had been lost, this should also have had an impact
on infections of higher intensity.
The high variability of repeated S. haematobium egg counts
[27] renders single egg counts a less than optimal tool for
estimating total prevalence and for identifying the
infection status of individuals. Our results however show
that estimates of the proportion of heavy infections and of
population infection intensity are similar to those
obtained when examining two specimens. The examina-
tion of three or more specimens per child would most cer-
tainly have led to even higher estimates of total prevalence
but we doubt that it would have changed the other two
estimates considerably.
All this indicates that the reporting of measures of infec-
tion intensity is not only important because they are a bet-
ter indicator of population morbidity than prevalence
[8,15], but that intensity is also a more reliable marker of
treatment success defined as the removal of egg-laying
worms. This is especially important when relying on sin-
gle egg counts to assess the effectiveness of the interven-
tion which is usually the case in treatment programmes
and larger field studies [28].
Re-infection
Because of the slow decrease in total prevalence after treat-
ment it did not seem appropriate to restrict analysis of re-
infection to those children who were egg-negative three
weeks after treatment. According to our above reasoning
this would have excluded a number of children who had
been treated successfully but were still excreting old eggs.
On the other hand we did not want to restrict the analysis
to those children who were found egg-negative at 41
weeks after treatment. Even though this was the survey
where we found the lowest prevalence, we might have
excluded children who had been treated successfully, but
had become re-infected again before this survey. Therefore
we included all children who were found egg-negative at
either 3, 16 or 41 weeks after treatment into the group at
risk of re-infection. We are, however, aware that this defi-
nition is likely to include some uncured children who
were still harbouring low level infections.
Our data indicate that S. haematobium transmission
occurred mainly during the hot and humid summer.
According to the literature, S. haematobium has a pre-pat-
ent period (infection to egg-excretion by the host) of
about eight to ten weeks [29,30]. Thus the surveys at 41
weeks and at 53 weeks after treatment should approxi-
mately reflect transmission from early May (treatment) to
early December and from early December to late February
respectively. The former period covers the South-African,
winter, spring and only a short part of the summerBMC Infectious Diseases 2004, 4:40 http://www.biomedcentral.com/1471-2334/4/40
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whereas the latter covers most of the hottest and wettest
part of the year (Figure 3), conditions which favour S. hae-
matobium transmission and the development of their Buli-
nus globosus snail hosts [31,32]. Moreover, children go
swimming more frequently because of the hot weather
and the long summer holidays in December and January
give them ample time to do so.
Seasonality of S. haematobium transmission is well docu-
mented for the highveld region of Zimbabwe[33] with
patterns rather similar to the ones found here, which seem
to be caused by seasonal variation in snail populations as
well as human water contact patterns [34]. A study in
southern Natal found that recreational activities
accounted for most of the water contact and – unlike
household related water contacts – showed strong sea-
sonal variation [35].
Conclusions
Our study shows that according to WHO guidelines [4]
the high prevalence and intensity of S. haematobium infec-
tion in the area indeed necessitate regular treatment of
schoolchildren, that praziquantel treatment is highly effi-
cacious in reducing the proportion of moderate and heavy
infections and that one treatment per year after the end of
summer is sufficient to keep infection intensities at low
levels. Because levels of S. haematobium infection in the
study area seem to be among the highest in the country
[23] the latter would probably also apply to other parts of
South Africa. The slow pace of re-infection might suggest
that it could even be sufficient to only treat every two
years, but this would need to be verified in a separate
study that follows treated children over this period.
Because we would not want to discourage future attempts
to control schistosomiasis in the region and elsewhere we
would finally like to stress that the above described
money and time consuming intensive examinations are
only required when doing research but that for a control
programme a minimum of surveillance is sufficient [4].
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